Access, Community Implementation, and Guideline Updates in Relapsed/Refractory Multiple Myeloma

The panel discusses geographic access, community-based treatment, and evolving guideline recommendations for BCMA-directed therapies in relapsed/refractory multiple myeloma. Dr. Douglas Sborov highlights the challenges faced by patients who live far from major myeloma centers, noting that prolonged travel can make CAR T-cell therapy difficult, while off-the-shelf bispecific antibodies and antibody-drug conjugates may provide additional treatment options closer to home. Dr. Paul Richardson discusses the perspectives of community hematologists and the need for alternatives to cellular therapy, including approaches that can be administered safely in outpatient settings. Dr. Hans Lee describes how supportive-care strategies, including prophylactic tocilizumab, may facilitate outpatient administration of bispecific antibodies and potentially expand access in community oncology practices. The discussion then turns to evolving US treatment guidelines and regulatory considerations for belantamab mafodotin-containing regimens. Dr. Richardson highlights the increasing availability of BCMA-directed options across different lines of therapy and discusses emerging efforts to combine belantamab mafodotin with other agents, including CELMoDs and additional immunotherapeutic approaches.